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Purpose: To retrospectively compare morphologic and metabolic
changes in bone metastases in response to systemic ther-
apy in patients with metastatic breast cancer (MBC) with




The institutional review board waived the requirement for
informed consent and approved this HIPAA-compliant
study. A retrospective analysis was performed with 102
women (mean age, 55 years) with MBC who received
systemic treatment. All patients underwent integrated
PET/CT before and after treatment. Two reviewers ana-
lyzed the images in consensus. Morphologic changes, in-
cluding morphologic patterns, and lesion attenuation were
evaluated. Standardized uptake value (SUV) and total le-
sion glycolysis (TLG) were analyzed to evaluate metabolic
changes. Uni- and multivariate analyses were performed
to identify factors that enabled response duration (RD) to
be predicted.
Results: At baseline, the morphologic patterns of the target lesions
were lytic (n  33), sclerotic (n  22), mixed (n  42),
and unclassified (n  5). Progression of sclerotic change
after treatment was identified in 49 patients (48%). After
treatment, the mean attenuation of the lesion increased,
whereas the mean SUV and TLG decreased. Increases in
attenuation correlated significantly with decreases in SUV
(r  0.510, P  .001) and TLG (r  0.491, P  . 001).
Univariate analysis revealed that the increase in attenua-
tion and the decrease in SUV were potential predictors of
RD. Multivariate analysis revealed that an increase in the
change in SUV was a significant predictor of RD (relative
risk, 2.4; P  .003).
Conclusion: A decrease in SUV after treatment was an independent
predictor of RD in patients with MBC who had bone me-
tastases.
 RSNA, 2008
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Bone is the most common site ofdistant metastasis, and metasta-ses to bone are diagnosed in
30%–85% of patients with advanced
breast cancer (1). Bone metastasis
causes much of the morbidity and dis-
ability in patients with breast cancer be-
cause of its potentially prolonged clini-
cal course. Proper assessment of treat-
ment response is essential for making
correct treatment decisions and im-
proving outcome.
Fluorine 18 fluorodeoxyglucose (FDG)
positron emission tomography (PET)
has been shown to be substantially
more accurate than conventional imag-
ing in the assessment of functional tu-
mor response to chemotherapy or hor-
mone therapy in patients with primary
breast cancer (2–5) and those with me-
tastatic breast cancer (MBC) (6–9).
Furthermore, the degree of the increase
in glycolysis has been found to enable
physicians to predict the outcome of
breast cancer (10). Although PET has
been proved to be an effective tool in
the care of patients with breast cancer,
it provides limited information on the
morphologic abnormalities in bone.
Three types of bone metastases (ie,
lytic, sclerotic, and mixed) often com-
plicate assessment of treatment out-
come (10–13).
Accurately co-registered functional
and morphologic data sets are gener-
ated with integrated PET/computed to-
mographic (CT) imaging systems, and
the initial results for diagnosis of skele-
tal metastasis with this combined func-
tional and morphologic system have
been promising (14). However, despite
the increasing use of integrated PET/CT
in the management of breast cancer, to
our knowledge, the clinical utility of
combined assessment of FDG avidity
and morphologic changes in breast can-
cer metastases to bone has not been
fully elucidated. Thus, the aim of our
study was to retrospectively compare
morphologic and metabolic changes in
bone metastases in response to sys-




Our institutional review board waived
the requirement for informed consent
and approved our Health Insurance
Portability and Accountability Act–
compliant study. A retrospective search
of our institutional PET/CT database re-
vealed 162 women who were referred
for staging of MBC and assessment of
the response of MBC to treatment be-
tween June 2003 and August 2006.
Sixty (37%) of the 162 patients origi-
nally identified as being eligible for this
study were later excluded because they
had a history of radiation therapy (n 
20), treatment with a granulocyte col-
ony–stimulating factor or erythropoie-
tin (n  17), concomitant malignancy
(n  17), or diabetes (n  2); because
of a severe metal artifact (n  1); or
because PET/CT revealed no discern-
able lesions in patients in whom bone
metastases had been identified with
bone scintigraphy only or magnetic res-
onance (MR) imaging only (n  3).
Thus, a total of 102 patients (mean age,
55 years; age range, 25–89 years) with
bone metastases from breast cancer
were ultimately included.
Chemotherapy and hormone ther-
apy were the preferred first-line treat-
ments for MBC in this study. Hormone
therapy consisted of administration of
an estrogen receptor antagonist (ta-
moxifen) or an aromatase inhibitor.
Chemotherapy alone was used to treat
widespread or life-threatening disease,
and patients with negative estrogen re-
ceptor findings underwent only chemo-
therapy. Combined chemotherapy and
hormone therapy was preformed in 76
patients, whereas 26 patients under-
went only chemotherapy.
Imaging
PET/CT was performed prior to sys-
temic therapy as a baseline study
(mean, 11 days; range, 0–18 days) and
after treatment (mean, 28 days; range,
21–38 days) in all patients. PET/CT im-
ages were acquired with an integrated
PET/CT device (Discovery ST-8; GE
Medical Systems, Milwaukee, Wis), and
the whole-body mode was implemented
as the standard software. Before PET/
CT, the patients fasted for at least 6
hours. All patients were tested to con-
firm that their glucose level was within
the normal range (80–120 mg/dL [4.4–
6.6 mmol/L]) before FDG administra-
tion. Before PET, unenhanced CT was
performed from the base of the skull to
the upper thigh according to a standard-
ized protocol performed with the fol-
lowing settings: transverse 3.75-mm
section thickness, 140 kVp, 120 mA,
and 13.5-mm table speed.
Emission scans were obtained 60
minutes after intravenous administration
of FDG (mean dose, 555 MBq; range,





FDG  fluorine 18 fluorodeoxyglucose
MBC  metastatic breast cancer
RD  response duration
SUV  standardized uptake value
TLG  total lesion glycolysis
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Advance in Knowledge
 A decrease in attenuation and an
increase in standardized uptake
value (SUV) of bone metastases
after systemic therapy are associ-
ated with a markedly increased
risk of disease progression in pa-
tients with metastatic breast can-
cer (MBC).
Implication for Patient Care
 A decrease in SUV of the lesion
after systemic therapy was an in-
dependent predictor of response
duration in patients with MBC
who had bone metastasis.
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3 minutes per bed position in the two-
dimensional mode. Images were recon-
structed with attenuation-weighted or-
dered-subset expectation maximization
with and without attenuation correction.
Image Interpretation and Morphologic
Analyses
PET and CT images obtained in all stan-
dard planes were reviewed on an Ad-
vance workstation (GE Medical Sys-
tems). Two reviewers (U.T., C.G.; each
with 2 years of experience) visually and
quantitatively analyzed the images and
recorded their findings after they reached a
consensus. For visual analysis, abnor-
mal FDG uptake was defined as sub-
stantially greater activity in tissue than
in the aortic blood on attenuation-cor-
rected images. Only the lesion that ex-
hibited the most substantial uptake was
selected as the target lesion for re-
sponse to therapy. A region of interest
(ROI) was outlined within areas of in-
creased FDG uptake and measured on
each section. When the lesion was ex-
tensively heterogeneous, the ROI was
set to cover all lesion components.
When abnormal FDG uptake was
present in bone, the exact anatomic lo-
cation of the abnormal uptake was iden-
tified on CT images. Patients were clas-
sified as having lytic, sclerotic, mixed,
or unclassified metastatic bone disease
at the time of diagnosis of bone metas-
tasis on the basis of the findings of the
CT portion of the PET/CT examination.
Unclassified disease included the lesions
that had minimal sclerotic or lytic change
when compared with the adjacent bone.
The morphologic changes observed on
CT scans were classified as lytic-pro-
gressive change, sclerotic-progressive
change, or structural change. The
change in CT attenuation (Att) (mea-
sured in Hounsfield units) in the ROI of
the entire lesion before and after treat-
ment was calculated with the following
equation: Att  [(Attpre  Attpost)/
Attpre]  100, where Attpre and Attpost
denote pre- and posttreatment attenua-
tion, respectively.
Standardized Uptake Value
The maximum standardized uptake
value (SUV) was calculated with the fol-
lowing equation: SUV  A/(ID/BW),
where A is the decay-corrected mean
activity in tissue (measured in millicur-
ies per milliliter), ID is the injected dose
of FDG (measured in millicuries), and
BW is the patient’s body weight (mea-
sured in grams). Changes in SUV
(SUV) after treatment were calculated
with the following equation: SUV 
[(SUVpre  SUVpost)/SUVpre]  100,
where SUVpre and SUVpost denote pre-
and posttreatment SUV, respectively.
Total Lesion Glycolysis
The change in total lesion glycolysis
(TLG), also called the Larson-Gins-
berg index, was calculated as the re-
sponse score (15) based on the volume
(V) obtained with PET and the aver-
age SUV with use of the following
equation: TLG  {[(SUVpre  Vpre) 
(SUVpost  Vpost)]/(SUVpre  Vpre)}  100,
where the subscripts “pre” and “post” re-
fer to the pre- and posttreatment values,
respectively.
Responders and Nonresponders
Two radiologists (U.T., C.G.) retro-
spectively reviewed the medical records
for follow-up findings detected at visual
analysis of PET/CT images, bone scinti-
grams, and MR images. In patients who
were designated as responders, the tar-
get lesion showed decreased uptake
when compared with the same lesion
depicted on baseline images. In nonre-
sponders, a follow-up examination re-
vealed FDG uptake in the target lesion
was substantially increased or similar to
that seen previously. When the target
lesion showed increased FDG uptake
compared to the baseline value, bone
scintigraphy and MR imaging were also
performed. Increased FDG uptake in
the target lesion, which was also sub-
stantially enlarged at MR imaging or had
positive bone scintigraphy findings, was
considered indicative of relapsed or
progressive disease.
Table 1
Baseline Characteristics of Patients
Characteristic Value




Treatment for bone metastasis
Hormone therapy and chemotherapy 76 (75)
Chemotherapy alone 26 (25)






Note.—Unless otherwise indicated, data are numbers of patients, and data in parentheses are percentages.
* Data are mean  standard deviation. Data in parentheses are the range.
Table 2











Formation of soft-tissue mass 7 (7)
Fracture 5 (5)
Periosteal reaction 1 (1)
Note.—Data in parentheses are percentages.
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Figure 1
Figure 1: FDG PET, CT, and FDG PET/CT images obtained before and after systemic therapy. Baseline transaxial (a) FDG PET, (b) correlative CT, and (c) PET/CT
images in a 49-year-old woman show bone metastasis in the thoracic spine at the level of the T11 vertebra (arrow). Mean values of attenuation, SUV, and TLG of the lesion
are 268.4 HU, 7.9 g/mL, and 439.8, respectively. Abnormal FDG uptake in the liver corresponds to hepatic metastasis. Transaxial (d) FDG PET, (e) correlative CT,
and (f) PET/CT images obtained 18 months after the start of hormone therapy and chemotherapy show progression of sclerotic change and metabolic reduction (arrow).
Different abnormal FDG uptake in the liver corresponds to a new lesion of hepatic metastasis. Mean values of attenuation, SUV, and TLG of the lesion are 309.0 HU, 2.8
g/mL, and 338.1, respectively. Thus, the increase in attenuation was 15.1%, whereas the decreases in SUV and TLG were 64.6% and 23.1%, respectively.
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Statistical Analysis
Comparison of mean values between
groups was performed with the Stu-
dent t test. Response duration (RD),
which was the period from the time at
which the patients met the criteria to
be considered responders to the time
at which the event occurred as the first
evidence of relapse or progression,
was chosen as the end point for as-
sessment of the prognostic value. The
time of the initial diagnosis of bone
metastasis was the starting time for
the assessment of RD. Univariate re-
gression analyses were performed
to assess the cumulative hazard of
disease progression by comparing
Kaplan-Meier survival curves and per-
forming log-rank tests. Multivariate Cox
proportional hazards regression analy-
ses were applied to test the indepen-
dence of established prognostic factors
in the prediction of disease progression.
P  .05 was considered to indicate a
significant difference. Statistical analy-
sis was performed with SPSS software
(version 12; SPSS, Chicago, Ill).
Results
Patients and Lesions
The median number of lesions per pa-
tient was four (range, 1–16 lesions per
patient). At the time of initial diagnosis,
target bone lesions were located in the
spine (n  74), ilium (n  15), sternum
(n  7), pubis (n  2), clavicle (n  1),
humerus (n  1), and femur (n  1), as
well as in a rib (n  1). Fifty-seven pa-
tients (56%) had a distant metastasis
in tissue other than bone at baseline
(Table 1). Diagnoses consisted of inva-
sive ductal carcinoma in 90 patients
(88%) and lobar carcinoma in 12
(12%). Pathologic studies revealed that
82 patients (80%) had estrogen recep-
tor–positive disease, 57 (56%) had pro-
gesterone receptor–positive disease,
and 19 (19%) showed signs of HER2
gene expression. After a median fol-
low-up period of 15 months (range,
1–36 months), 77 patients (75%) were
still alive, whereas 25 patients (25%)
had died from their disease.
Target bone lesions (Table 2) were
distributed in the medulla in 62 patients
(61%) and in both the cortex and the
medulla in 35 patients (34%). In five
patients, the lesion seen on the CT por-
tion of the PET/CT study was faint and
its distribution was unclear. Specific
findings were present in 13 patients
(13%) and included formation of a soft-
tissue mass (n  7), fracture (n  5),
and periosteal reaction (n  1). How-
ever, most patients (n  90, 88%) did
not have a specific finding.
Lesion Morphology and Follow-up
The morphologic pattern of the target
lesions on the baseline PET/CT images
was classified as lytic in 33 patients
(32%), sclerotic in 22 (22%), mixed in
42 (41%), and unclassified in five (5%).
After treatment, however, the morpho-
logic pattern of the target lesions was
classified as lytic in 15 patients (15%),
sclerotic in 35 (34%), mixed in 51
(50%), and unclassified in one patient
(1%). Progression of sclerotic change
after treatment (Fig 1) was identified in
49 patients (48%).
The mean attenuation of the lesion
evaluated on the CT portion of the
PET/CT study increased after treat-
ment. In contrast, systemic therapy
resulted in a decrease in the mean
SUV and in the mean TLG when com-
Figure 2
Figure 2: Scatterplot shows the relationship
between SUV and TLG. The change in SUV was
positively correlated with the change in TLG (r 
0.614, P  .001).
Table 3
PET/CT Parameters at Baseline and
After Treatment
Parameter Baseline After Treatment
Attenuation
(HU)
Mean* 284.6  161.5 336.4  197.8
Range 20.6–758.2 26.3–861.1
SUV (g/mL)
Mean* 7.9  5.6 7.2  5.5
Range 2.0–26.7 1.5–26.2
TLG
Mean* 50.9  71.3 42.6  38.9
Range 2.1–627.1 2.3–197.3
* Data are mean values  standard deviations.
Table 4





(n  52) Overall P Value
Change in attenuation (%)
Mean* 8.0  56.8 26.3  52.4 15.8  54.5 .09
Range 190.5 to 64.1 229.2 to 23.6 249.2 to 94.9
Change in SUV (%)
Mean* 42.6  81.8 12.5  66.7 16.1  78.7 .001
Range 228.0 to 85.2 239.0 to 77.4 239.0 to 85.2
Change in TLG (%)
Mean* 19.9  73.8 1.9  61.5 11.5  68.2 .18
Range 186.0 to 94.2 197.9 to 90.4 197.9 to 94.2
Note.—Nonresponders were patients with a target lesion that showed substantial increase or a value similar to that seen
previously. Responders were patients with a target lesion that showed decreased uptake compared with baseline values.
* With the exception of the P values, data are mean values  standard deviations.
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pared with baseline values (Table 3).
The decrease in SUV was significantly
larger in responders than in nonre-
sponders (P  .001, Table 4); how-
ever, no significant difference between
responders and nonresponders was found
for the increase in attenuation or the
increase in TLG. There was a significant
linear relationship between the de-
crease in SUV and the decrease in TLG
(r  0.614, P  .001; Fig 2). The in-
crease in attenuation correlated signifi-
cantly with the decrease in SUV (r 
0.510, P  .001; Fig 3) and the de-
crease in TLG (r  0.491, P  .001;
Fig 4).
Univariate analysis was performed
by using variables that have been sug-
gested to be associated with the inci-
dence of progression (Table 5), and
both the increase in attenuation and
the decrease in SUV were identified as
potential predictors of the incidence
of progression (Fig 5). Patient age,
primary tumor, treatment, distri-
bution, specific findings, sclerotic
change, and decrease in TLG did not
add predictive value for incidence of
progression. The final multivariate anal-
ysis revealed that a decrease in SUV
of 8.5% or more was a significant pre-
dictor of RD (relative risk, 2.4; 95%
confidence interval: 1.3, 4.4; P 
.003).
Discussion
Our results showed that an increase in
attenuation and a decrease in SUV of
bone metastases after systemic treat-
ment are associated with RD in patients
with MBC. Uni- and multivariate Cox
regression analyses showed that a de-
crease in SUV of 8.5% or more was a
significant predictor of a long RD.
PET contributes to the detection of
lytic bone metastasis, which is associ-
ated with a poorer prognosis than is
sclerotic metastasis (10). The FDG
avidity of bone metastases in patients
with MBC depends on the metastasis
type. We found that an increase in the
attenuation of bone metastases corre-
lates with a decrease in SUV or TLG.
This finding appears to corroborate
Figure 3
Figure 3: Scatterplot shows the relationship
between attenuation and SUV. The increase in
attenuation was negatively correlated with the
decrease in SUV (r  0.510, P  .001).
Figure 4
Figure 4: Scatterplot shows the relationship
between attenuation and TLG. The increase in
attenuation was negatively correlated with the
decrease in TLG (r  0.491, P  .001).
Table 5













Hormone therapy and chemotherapy 76 41
Chemotherapy alone 26 58
Distribution .82
Medulla 62 47






Lesions exhibiting progression of sclerotic change 49 48
Lesions with no progression of sclerotic change 53 34
Change in attenuation (%) .05
Less than 8.6 49 33
Greater than or equal to 8.6 53 44
Change in SUV (%) .01
Less than 8.5 49 50
Greater than or equal to 8.5 53 27
Change in TLG (%) .80
Less than 0.03 51 49
Greater than or equal to 0.03 51 42
Note.—NA  not applicable.
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the results of a previous study (15).
Morphologic and metabolic assess-
ment of bone metastasis with PET/CT
can assist in monitoring the response
to systemic therapy for bone metasta-
ses in patients with MBC.
Change in TLG (TLG) is the ratio
of the metabolic rate of the tumor at
baseline to the metabolic rate of the
tumor after treatment. TLG corre-
sponds to the change in the cell mass of
the target lesion and reflects the global
response of the entire tumor to treat-
ment (15). In a study of 15 patients with
rectal cancer, TLG was shown to be a
strong predictor of disease-specific and
recurrence-free survival (16). It is im-
portant to note that other investigators
found that TLG reflected treatment re-
sponse in patients with several types of
locally advanced cancers and revealed
information complementary to that ob-
tained with SUV analysis. In contrast,
our data showed that TLG did not en-
able us to predict RD in patients who
had bone metastases. The discrepancy
between these findings may be related
to the minimal changes in the volume of
target bone lesions.
Metabolic reduction after treatment
has been suggested to be of value in the
assessment of treatment efficacy in a
variety of solid tumors (17–22). A change
in tumor size after treatment is fre-
quently used to evaluate therapeutic re-
sponse in patients with breast cancer
(23). However, patients with bone me-
tastasis have often been excluded from
clinical trials because bone metastases
are considered immeasurable. On the
other hand, PET/CT enables semiquan-
titative assessment of uptake, which
makes it convenient to use when evalu-
ating tumor viability during treatment.
Our findings showed that patients who
had bone metastasis and metabolic re-
duction with an SUV decrease of 8.5%
or more after treatment had a 2.4-fold
higher relative risk of a long RD during
follow-up.
In regard to the generation of data
to aid in the prediction of outcome, the
inclusion of patients who developed dis-
tant metastases to tissue other than
bone during the course of the disease
was a limitation of our study because
the presence of distant metastases in
other tissues can have a considerable
effect on patient outcome. In a study of
patients with advanced breast cancer,
researchers found a wide variation in
survival rates and showed that 20% of
the patients with bone metastases sur-
vived for more than 5 years (24). There-
fore, we used RD as the primary end
point to evaluate the value of PET/CT
findings as a predictor of therapeutic
efficacy.
Our study had other potential limi-
tations. It may not have been sufficiently
powered for the demonstration of sig-
nificant differences among some of the
covariates because we assessed only
one target lesion per patient. However,
the strength of our primary outcome, as
well as the historic precedence of a sig-
nificant predictor in the multivariate
analysis, lends credence to our conclu-
sions. Since data collection was per-
formed retrospectively, selection bias
may have affected our results. There
may have been another aspect of bias in
our study. The enrolled patients under-
went one of two treatments for bone
metastasis: (a) hormone therapy and
chemotherapy and (b) chemotherapy
alone. Further prospective studies are
needed to assess the treatment effect of
one standard regimen for bone metasta-
sis with use of PET/CT. In our study, it
was unclear whether PET/CT proved to
be more cost-effective than conventional
strategies. However, to our knowledge, the
Figure 5
Figure 5: (a) Graph shows cumulative probability of progression of bone metastases in patients with an attenuation increase of 8.6% or more (solid line) and those
with an attenuation increase of less than 8.6% (dashed line). A significant difference in cumulative hazard of progression was found between the groups at log-rank test-
ing (P  .05). (b) Graph shows cumulative probability of progression of bone metastases in patients with an SUV decrease of 8.5% or more (solid line) and those with an
SUV decrease of less than 8.5% (dashed line). A significant difference in cumulative hazard of progression was found between the groups at log-rank testing (P  .01).
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costs and health outcomes associated
with PET/CT in addition to those of con-
ventional studies for MBC in clinical
practice have not been assessed in the
clinical or economic context. Clinical
trials are needed to determine the cost-
effectiveness of PET/CT in the care of
patients with MBC.
In conclusion, our study results pro-
vide evidence that the change in SUV of
bone metastasis after treatment is
highly predictive of RD in patients with
MBC. The predictive power of this pa-
rameter for long RD needs to be vali-
dated in a prospective study, and we
plan to conduct such a study at our in-
stitution.
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